Management of hepatocellular carcinoma: An update
By Jordi Bruix1 , 2, M. Sherman. Hepatology, 2011
8,421 citations recorded by the source corpus.
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated. The full version of the new guidelines is available on the AASLD Web site at http://www.aasld.org/practiceguidelines/Documents/Bookmarkedp20Practice%20Guidelines/HCCUpdate2010.pdf. Here, we briefly describe only new or changed recommendations.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/c74d6d394cb52fd2ca5716998c90326bf823ea30
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Amit G. Singal
- Z. Younossi
- Alejandro Forner1 , 2
- L. Kulik
Citations in the corpus
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “However, if technically feasible they may benefit from surgical resection, and these patients should be classified as BCLCA.1,87,318 Another rare subgroup are patients with large multifocal HCC affecting both lobes, without vascular invasion or extrahepatic spread, as major tumour burden is usually ”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, methodology): “An accepted rule is to consider any nodule larger than about 1 cm as an abnormal screening result warranting further investigation [56].”
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “The problem is further heightened by a current lack of effective preventive strategies for HCC in subjects with cirrhosis.((40)) There is therefore a need to tackle the problem of HCC at multiple levels.”
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017, methodology): “…or non-invasive assessment according to the American Association for the Study of Liver Diseases criteria for patients with confi rmed cirrhosis, 1 and had to have at least one measurable lesion by modifi ed Response Evaluation Criteria in Solid Tumors for HCC (mRECIST) 22 and RECIST version 1.1.”
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, methodology): “Patients with NASH cirrhosis should be considered for HCC screening according to the AASLD/ACG practice guidelines.(182)(Strength – 1, Quality – B)”
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, background): “2) may offer the most prognostic information because it includes an assessment of tumor burden, liver function, and patient PS and thereby has been endorsed by the societies that specialized in liver disease.(3,94) The prognostic ability of the BCLC has been validated in European, American, and Asia”
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, background): “2) may offer the most prognostic information because it includes an assessment of tumor burden, liver function, and patient PS and thereby has been endorsed by the societies that specialized in liver disease.(3,94) The prognostic ability of the BCLC has been validated in European, American, and Asia”
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “2 %/year in hepatitis B infected subjects without cirrhosis [361].”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, methodology): “An accepted rule is to consider any nodule larger than about 1 cm as an abnormal screening result warranting further investigation [56].”
- Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma (2016, methodology): “radioembolization with yttrium-90 microspheres [Y90]), appear in guidelines as treatment options for HCC.(2-4) For early disease ([Barcelona Clinic Liver Cancer] BCLC A), ablation is recommended.”